Exelixis, Inc. — Form 10-Q Summary
Period discrepancy: The request identifies 2019 Q2, but the supplied filing is Exelixis’s 2020 second-quarter Form 10-Q, filed August 6, 2020. It covers the quarter and six months ended June 30, 2020 (fiscal quarter ended July 3, 2020, presented as June 30 for convenience); comparatives are 2019.
Business context
Exelixis is an oncology-focused biotechnology company. Its principal commercial product is CABOMETYX (cabozantinib); it also markets COMETRIQ and receives collaboration revenue from partners, including Ipsen, Takeda and Genentech. The company reported one operating segment.
Financial performance
| Metric | Q2 2020 | Q2 2019 | Six months 2020 | Six months 2019 |
|---|---|---|---|---|
| Total revenue | $259.5m | $240.3m | $486.4m | $455.8m |
| Net product revenue | $178.7m | $193.7m | $372.6m | $373.3m |
| Operating income | $75.5m | $92.0m | $128.3m | $176.5m |
| Net income | $66.8m | $79.0m | $115.4m | $154.8m |
| Diluted EPS | $0.21 | $0.25 | $0.36 | $0.49 |
| Operating cash flow | Not separately stated for the quarter | $157.8m | $293.3m |
- Q2 license revenue rose 57% to $59.2m and collaboration services revenue rose 143% to $21.5m. Revenue included milestone amounts from Takeda’s Japan launch and an Ipsen development milestone.
- Q2 CABOMETYX revenue fell 8% to $173.6m; COMETRIQ revenue increased 10% to $5.1m. The company attributed lower CABOMETYX unit sales partly to COVID-19-related patient-access obstacles and ordering fluctuations.
- Q2 R&D expense increased 40% to $114.9m, principally reflecting expanded cabozantinib trials. SG&A was $59.8m, up 2%. Gross margin was 95% versus 96%; operating margin was approximately 29% versus 38%.
- At June 30, cash and cash equivalents were $527.1m, short-term investments $685.9m and long-term investments $327.1m, totaling approximately $1.54bn in cash and investments. Total liabilities were $213.2m; the filing does not present a borrowing balance or report material off-balance-sheet arrangements.
- Six-month operating cash flow declined to $157.8m from $293.3m, which management attributed mainly to higher operating expense cash outlays, $33.0m less in milestone payments received, and other working-capital changes. Investing activities provided $105.9m, largely reflecting investment maturities and sales.
Material changes, outlook and commentary
- Management expected 2020 second-half net product revenue to remain in line with 2019’s comparable period; it expected license revenue to decrease due to fewer anticipated milestones, collaboration services revenue to increase with development reimbursements, and R&D and SG&A expenses to rise. The filing does not provide a specific full-year revenue or earnings forecast.
- Management stated that available cash, investments and anticipated product and collaboration revenues were expected to fund operations for at least 12 months after filing. It also noted that pipeline expansion and development spending could require debt or equity financing.
- Clinical and pipeline updates included positive top-line CheckMate-9ER results in first-line advanced renal cell carcinoma; the company planned to submit an sNDA in Q3 2020. It also planned a COSMIC-311 interim analysis in the second half of 2020 and expected COSMIC-312 top-line results in the first half of 2021.
- COVID-19 had a modest reported impact at the time: reduced CABOMETYX demand and trial-site activity, and modest early discovery delays. The company reported no significant supply-chain disruption and cited substantial safety stock, while warning that worsening conditions could delay trials, reduce sales or disrupt operations.
- In the MSN patent dispute over a proposed generic CABOMETYX, consolidated litigation was scheduled for a May 2022 bench trial. The company said an early generic launch could materially reduce revenue; the likelihood and potential loss were not estimable.
- A $5.4m estimate adjustment for the Branded Prescription Drug Fee increased SG&A in Q1 2020 and reduced first-half basic and diluted EPS by $0.02. The fee accrual was $15.1m at June 30, 2020.
Most important facts to verify
- Confirm the intended period: the supplied filing is Q2 2020, not Q2 2019.
- Track CABOMETYX prescription demand, gross-to-net discounts and the persistence of COVID-19 effects.
- Check trial milestones, regulatory submissions and whether rising R&D spending produces successful approvals.
- Monitor the MSN patent litigation and the durability of CABOMETYX market exclusivity.
- Review cash generation against operating and development spending, and confirm management’s liquidity outlook as circumstances change.